Effects of tacrolimus ointment on Toll-like receptors in atopic dermatitis

Clinical and Experimental Dermatology

Volumn 36, Issue 3, 2011, Pages 235-241

  Antiga, E ^a   Volpi, W ^a   Torchia, D ^a   Fabbri, P ^a   Caproni, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE BUTYRATE; TACROLIMUS; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MALE; OINTMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SKIN BIOPSY; TOPICAL TREATMENT; TREATMENT DURATION;

ADULT; AGED; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; FEMALE; HUMANS; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; SKIN; TACROLIMUS; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTORS; YOUNG ADULT;

EID: 79952805993     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03948.x     Document Type: Article

References (24)

1. Jin H, Kumar L, Mathias C et al. Toll-like receptor 2 is important for the T(H)1 response to cutaneous sensitization. J Allergy Clin Immunol 2009; 123: 875-82.e1.
2. Petry V, Gaspari AA. Toll-like receptors and dermatology. Int J Dermatol 2009; 48: 558-70.
3. Mrabet-Dahbi S, Dalpke AH, Niebuhr M et al. The Toll-like receptor 2 R753Q mutation modifies cytokine production and Toll-like receptor expression in atopic dermatitis. J Allergy Clin Immunol 2008; 121: 1013-19.
4. Oh DY, Schumann RR, Hamann L et al. Association of the toll-like receptor 2 A-16934T promoter polymorphism with severe atopic dermatitis. Allergy 2009; 64: 1608-15.
5. El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 2009; 54: 76-87.
6. Alomar A, Berth-Jones J, Bos JD et al. European Working Group on Atopic Dermatitis. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004; 151 (Suppl. 70): 3-27.
7. Ahmad-Nejad P, Mrabet-Dhabi S, Breuer K et al. The toll-like receptor 2 R753K polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 2004; 113: 482-8.
8. Niebuhr M, Langnickel J, Draing C et al. Dysregulation of toll-like receptor-2 (TLR-2) -induced effects in monocytes from patients with atopic dermatitis: impact of the TLR-2 R753Q polymorphism. Allergy 2008; 63: 728-34.
9. Xie ZQ, Liu LL, Yang GY, Zhu XJ. Effecs of topical tacrolimus ointment on expression of Toll-like receptors 2 and 4 in lesional atopic dermatitis skin. Beijing Da Xue Xue Bao 2006; 38: 420-3 (Abstract).
10. Caproni M, Torchia D, Antiga E et al. The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis. J Clin Immunol 2006; 26: 370-5.
11. Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195: 10-19.
12. Jarrousse V, Quereux G, Marques-Briand S et al. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Eur J Dermatol 2006; 16: 636-41.
13. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430: 257-63.
14. Ochoa MT, Legaspi AJ, Hatziris Z et al. Distribution of Toll-like receptor 1 and Toll-like receptor 2 in human lymphoid tissue. Immunology 2003; 108: 10-15.
15. Hajjar AM, O'Mahony DS, Ozinsky A et al. Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 2001; 166: 15-19.
16. Weidinger S, Novak N, Klopp N et al. Lack of association between Toll-like receptor 2 and Toll-like receptor 4 polymorphisms and atopic eczema. J Allergy Clin Immunol 2006; 118: 277-9.
17. Terhorst D, Kalali BN, Weidinger S et al. Monocyte-derived dendritic cells from highly atopic individuals are not impaired in their pro-inflammatory response to toll-like receptor ligands. Clin Exp Allergy 2007; 37: 381-90.
18. Niebuhr M, Langnickel J, Siegel S, Werfel T. Dysregulation of CD36 upon TLR-2 stimulation in monocytes from patients with atopic dermatitis and the TLR2 R753Q polymorphism. Exp Dermatol 2010; 19: e296-8.
19. Hasannejad H, Takahashi R, Kimishima M et al. Selective impairment of Toll-like receptor 2-mediated proinflammatory cytokine production by monocytes from patients with atopic dermatitis. J Allergy Clin Immunol 2007; 120: 69-75.
20. Takeuchi O, Hoshino K, Akira S. Citting edge. TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000; 165: 5392-6.
21. Fageras BottcherM, Hmani-Aifa M, Lindstrom A. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12 (p70) responses in Swedish children. J Allergy Clin Immunol 2004; 114: 561-7.
22. Novak N, Yu CF, Bussmann C et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 2007; 62: 766-72.
23. Kis K, Bodai L, Polyanka H et al. Budesonide, but not tacrolimus, affects the immune functions of normal human keratinocytes. Int Immunopharmacol 2006; 6: 358-68.
24. Hung SH, Lin YT, Chu CY et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol 2007; 98: 51-6.